This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

31 Drugs Facing FDA Approval in 2012-2013

BOSTON ( TheStreet) -- Here's an updated list of biotech and pharmaceutical companies with pending FDA drug approval decisions for the rest of 2012 and into early 2013. This refresh includes changes and additions to the FDA calendar last published at the end of July.

The calendar on the following pages captures the most important U.S. regulatory events -- FDA drug approvals and advisory panels -- expected between August and March 2013. As every savvy biotech investor and trader knows, the volatility in biotech and drug stocks ramps significantly as U.S. regulators weigh whether to approve or reject new drugs.

Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst.

Gilead Sciences (GILD)
Drug/indication: Quad for HIV
Approval decision date: Aug. 27
Quad combines four Gilead drugs into a single, once-daily pill for HIV. The new (and still experimental) components in the Quad are the integrase inhibitor elvitegravir and cobicistat, which is used to boost blood levels of elvitegravir.

Pfizer (PFE)
Drug/indication: Tofacitinib for rheumatoid arthritis
Approval decision date: August (exact date not specified)
Tofacitinib would be the first pill approved for the treatment of rheumatoid arthritis, competing with established injectable drugs like Abbbot's Humira.

Ironwood Pharmaceuticals (IRWD - Get Report)
Drug/indication: Linaclotide for chronic idiopathic constipation and irritable bowel syndrome
Approval decision date: Sept. 7

Navidea Biopharmaceuticals (NAVB - Get Report)
Drug/indication: Lymphoseek, a radioactive tracing agent for lymph node mapping
Approval decision date: Sept. 10

Sanofi (SNY)
Drug/indication: Aubagio for multiple sclerosis
Approval decision date: Sept. 12

Cornerstone Therapeutics (CRTX)
Drug/indication: Lixivaptan for hyponatremia
FDA advisory panel: Sept. 13
Approval decision date: Oct. 29

Regeneron Pharmaceuticals (REGN)
Drug/indication: Eylea for Retinal Vein Occlusion (RVO)
Approval decision date: Sept. 21
This is an additional indication for currently approved Eylea.

Bristol-Myers Squibb (BMY)
Drug/indication: Metreleptin for lipodystrophy
Approval decision date: Oct. 3

Drug/indication: Abraxane for non-small cell lung cancer
Approval decision date: Oct. 12
Abraxane is already approved for the treatment of breast cancer.

Bayer and Onyx Pharmaceuticals (ONXX)
Drug/indication: Regorafenib for metastatic colon cancer
Approval decision date: Oct. 15-30 (No specific date disclosed)

Santarus (SNTS)
Drug/indication: Uceris for ulcerative colitis
Approval decision date: Oct. 16

Aegerion Pharmaceuticals (AEGR)
Drug/indication: Lomitapide for dyslipidemia/hypercholesterolemia
FDA advisory panel: Oct. 17
Approval decision date: Dec. 28

Sanofi and Isis Pharmaceuticals (ISIS)
Drug/indication: Kynamro for dyslipidemia/hypercholesterolemia
FDA advisory panel: Oct. 18
Approval decision date: Jan. 29, 2013

Impax Labs (IPXL)
Drug/indication: IPX066 for Parkinson's disease
Approval decision date: Oct. 19

Hyperion Therapeutics (HPTX)
Drug/indication: Ravicti for urea cell disorders
Approval decision date: Oct. 23

United Therapeutics (UTHR)
Drug/indication: Oral Remodulin for pulmonary arterial hypertension
Approval decision date: Oct. 26

Exelixis (EXEL)
Drug/indication: Cabozantinib for medullary thyroid cancer
FDA advisory panel: Nov. 9
Approval decision date: Nov. 29
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CRTX $0.00 0.00%
HPTX $45.99 0.04%
EXEL $4.33 0.00%
HEB $0.13 0.00%
IRWD $10.22 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs